https://www.live-feeds.com/feed/amylyx-stock-surges-55-after-glp-1-blocker-hits-all-trial-goalsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/amylyx-stock-surges-55-after-glp-1-blocker-hits-all-trial-goalshttps://www.live-feeds.com/feed/amylyx-stock-surges-55-after-glp-1-blocker-hits-all-trial-goals#u45451Thu, 20 Aug 2026 04:35:36 +0000Amylyx shares surged 55% following positive Phase 3 trial results for avexitide, a GLP-1 antagonist. The endocrine drug met all trial goals by reducing low blood sugar episodes in patients who underwent bariatric surgery. Fierce Biotech reports the inhibitor halved blood sugar crashes, prompting the company to prepare for a regulatory approval push. This success marks a late-stage win for the company as it shifts its focus following its previous work in ALS treatments.Why it mattersThe company is undergoing a strategic reset after its focus on ALS. This pivot into endocrine drugs targets compl